China Peptides Intelligence Profile
Research Incomplete
Research coverage for this vendor is 77%. Our research on China Peptides remains incomplete — what we have verified so far is published below, and research is continuing.
Still to research:
- Research coverage ≥ 80%
- Registration jurisdiction researched (state_of_registration)
- Refund policy reviewed (refund_return_policy)
- Payment methods reviewed (accepted_payment_methods)
- Public summary reviewed
Overview#
China Peptides (QYAOBIO / Qiangyao) is a Shanghai-based custom peptide, antibody, and protein synthesis company founded in 2008 per the vendor (domain chinapeptides.com registered 2008-10-28), selling made-to-order research-grade peptides (crude to 98% purity, mg to multi-kg, 400+ modifications) directly to researchers worldwide in its own name via its own Chinese and English sites — online order application and email quotation, no retail checkout, no published prices, payment methods, refund policy, or shipping rates. GATE: PASS on the direct-sales prong only — no U.S. legal entity, office, address, or phone was found in any source, but U.S. buyers can and do order directly from the vendor (documented example: Yale University, New Haven, CT, researchers listing peptides synthesized by ChinaPeptides Co., Ltd., Shanghai), and no independent-U.S.-distributor-only pattern was found. Regulatory record: all defined searches (FDA warning letters, recalls, import alerts, FTC, state AG, civil litigation, criminal/injunctive) returned No Record Found for THIS vendor; the 2012 FDA warning letter and 2026 House committee letter naming 'Chinese Peptide Company' of Hangzhou are a different company and must never be attributed to this profile. Testing evidence is vendor-generated only: HPLC/MS reports stated to accompany syntheses, no public COA library, no named independent lab, no verification portal, no dated COA sampled. Principal gaps are corporate-registry verification (exact Chinese legal entity; Shanghai/Suzhou/Hubei Qiangyao mapping) and unpublished commercial terms. No serious findings.
Company Identity#
Domain and Digital Identity#
Regulatory and Legal History#
Testing and COA Evidence#
Payment, Refund and Shipping#
Material Changes#
No material changes recorded.